Effects of the I(kr)-blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study

Cardiovascular Drugs and Therapy

Volumn 13, Issue 4, 1999, Pages 329-338

  Houltz, Birgitta ^a   Darpö, Börje ^b   Swedberg, Karl ^a   Blomström, Per ^c   Brachmann, Johannes ^d   Crijns, Harry J G M ^e   Jensen, Steen M ^f   Svernhage, Elisabeth ^g   Vallin, Hans ^b   Edvardsson, Nils ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Almokalant; Atrial fibrillation; Class III antiarrhythmic drugs; Conversion; Electrocardiographic variables; I(kr) blockers; Prediction

Indexed keywords

ALMOKALANT; AMIODARONE; SOTALOL; ANTIARRHYTHMIC AGENT; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; ELECTROCARDIOGRAM; ELECTROGRAPHY; FEMALE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; T WAVE; TIME; TORSADE DES POINTES; DRUG EFFECT; ELECTROCARDIOGRAPHY; GENETICS; HEART ATRIUM FIBRILLATION; MULTICENTER STUDY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; PROPANOLAMINES; TIME FACTORS; TORSADES DE POINTES;

EID: 0033162985     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007759500274     Document Type: Article

References (40)

1. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
2. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 1996;156:49-53.
3. Reisingers J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-1454.
4. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter A multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J 1995;129:739-748.
5. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079-1082.
6. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
7. Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K, Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J 1990;11:145-148.
8. Donovan KD, Dobb GJ, Coombs LJ, et al. Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 1992:70:50A-55A.
9. Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW. The Cardiac Arrhythmia Suppression Trial: First CAST... then CAST-II. J Am Coll Cardiol 1992;19:894-898.
10. Podrid PJ, Andersen JL. Safely and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996;78:430-434.
11. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998;21:108-120.
12. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998;32:169-176.
13. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-136.
14. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-1621.
15. Crijns HJGM, Golitsyn SR, Ruda MY, et al. Superiority of ibutilide over dl-sotalol in termination of atrial fibrillation and flutter: Results of a multinational trial (abstract). Eur Heart J 1996;17:583.
16. Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159-166.
17. Bianconi L, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind placebo-controlled study (abstract). Circulation 1995;92(suppl 1):1-774.
18. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997;29:385-390.
19. Darpö B, Almgren O, Almokalant-A selective class III antiarrhythmic compound. Cardiovasc Drug Rev 1996;14:60-83.
20. Darpö B, Almgren O, Bergstrand R, et al. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and antrioventricular nodal function in the heart: A study in healthy, male volunteers utilizing transesophageal atrial stimulation. J Cardiovasc Pharmacol 1995;25:681-690.
21. Darpö B, Vallin H, Almgren O, Bergstrand R, Insulander P, Edvardsson N. Selective Ik blocker almokalant exhibits class III-specific effects on the repolarization and refractoriness of the human heart: A study of healthy volunteers using right ventricular monophasic action potential recordings. J Cardiovasc Pharmacol 1995;26:530-540.
22. 1 of the class III effects of almokalant: A study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals. Cardiovasc Drugs Ther 1996;10:539-547.
23. Darpö B, Edvardsson N. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: A study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. J Cardiovasc Pharmacol 1995;26:198-206.
24. Darpö B, Edvardsson N. Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group. Cardiovasc Drugs Ther 1997;11:499-508.
25. Bazett H. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-369.
26. Houltz B, Darpö B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. Pacing Clin Electrophysiol 1998;21:1044-1057.
27. Capucci A, Villani GQ, Aschieri D. Risk of complications of atrial fibrillation. Pacing Clin Electrophysiol 1997;20:2684-2691.
28. Crijns HJGM, Kingma JH, Gosselink ATM, Dalrymple HW, De Langen CDJ, Lie K. Sequential bilateral bundle branch block during dofetilide, a new class III antiarrhythmic agent, in a patient with atrial fibrillation. J Cardiovasc Electrophysiol 1993;4:459-466.
29. Ramdat Misier AR, Opthof T, van Hemmel NM, et al. Increased dispersion of "refractoriness" in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992;19:1531-1535.
30. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
31. Carlsson L, Abrahamsson G, Andersson B, Duker G, Schiller Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993; 27:2186-2193.
32. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-1419.
33. Tieleman RG, Gosselink ATM, Crijns HJGM, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79:53-57.
34. Hoffman BF, Bigger JT Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics; 7th ed. New York: MacMillan Publishing Company, 1985:716-747.
35. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997;18:649-654.
36. Roden DM. Torsade de pointes. Clin Cardiol 1993;16:683-686.
37. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994;23:259-277.
38. Surawicz B, Knoebel SB. Long QT: Good, bad or indifferent? J Am Coll Cardiol 1984;4:398-413.
39. Locati KH, Maison Blanche P, Dejode P, Cauchemez B, Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: Quantitative analysis of Holter recordings. J Am Coll Cardiol 1995;25:1564-1575.
40. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94:2535-2541.